Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group.
Publication/Presentation Date
4-1-2023
Abstract
Recent studies have shown that microtransplant (MST) could improve outcome of patients with elderly acute myeloid leukemia (EAML). To further standardize the MST therapy and improve outcomes in EAML patients, based on analysis of the literature on MST, especially MST with EAML from January 1st, 2011 to November 30th, 2022, the International Microtransplant Interest Group provides recommendations and considerations for MST in the treatment of EAML. Four major issues related to MST for treating EAML were addressed: therapeutic principle of MST (1), candidates for MST (2), induction chemotherapy regimens (3), and post-remission therapy based on MST (4). Others included donor screening, infusion of donor cells, laboratory examinations, and complications of treatment.
Volume
9
Issue
4
First Page
14924
Last Page
14924
ISSN
2405-8440
Published In/Presented At
Ai, H., Chao, N. J., Rizzieri, D. A., Huang, X., Spitzer, T. R., Wang, J., Guo, M., Keating, A., Krakow, E. F., Blaise, D., Ma, J., Wu, D., Reagan, J., Gergis, U., Duarte, R. F., Chaudhary, P. M., Hu, K., Yu, C., Sun, Q., Fuchs, E., … Ma, L. (2023). Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group. Heliyon, 9(4), e14924. https://doi.org/10.1016/j.heliyon.2023.e14924
Disciplines
Medicine and Health Sciences
PubMedID
37089296
Department(s)
Department of Medicine, Lehigh Valley Topper Cancer Institute
Document Type
Article